1. Scrip

AbbVie May Be Poised For An Oral RA Smack Down

 
• By Joseph Haas

Upadacitinib hit the primary endpoints in the first of six Phase III studies in rheumatoid arthritis, as well as several important secondary endpoints. Continued success in Phase III will position the candidate well in the race to market with Lilly.

AbbVie Inc. unveiled promising top-line data from SELECT-NEXT, the first of six Phase III trials of JAK1 inhibitor upadacitinib (ABT-494) in rheumatoid arthritis June 7. Upadacitinib could have a chance to jump ahead of Eli Lilly & Co./Incyte Corp.'s baricitinib in the race to become the first in a new generation of JAK inhibitors to reach the market.

Analysts covering the data unanimously predicted eventual blockbuster sales for upadacitinib, a selective inhibitor of Janus kinase 1, with Jefferies Equity Research's Jeffrey Holford saying a peak estimate of $3.5bn across several autoimmune indications might be too low

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

More from Scrip

Finance Watch: Deerfield Closes $600m-Plus VC Fund; Gates Speeds Up Health Investments

 
• By Mandy Jackson

Private Company Edition: Deerfield’s third innovations fund will back therapeutics and other opportunities, the Gates Foundation – a sometimes funder of biotech firms – will spend $200bn over the next 20 years, and NewLimit raised a $130m series B round, among other financings.

Pipeline Watch: Six Approvals And Thirteen Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Pharma Left Hanging After US/UK Trade Pact

 
• By Kevin Grogan

An ‘historic economic prosperity deal’ does not include the sector.